BCP
TEVA icon

BSN Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

BSN Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,000,000
Closed -$50.7M – 20
2022
Q4 		$50.7M Buy
+6,000,000
New +$52.4M 3.59% 6

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

BSN Capital Partners's TEVA Position: Q1 2023 in Review

BSN Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2023, closing a stake of 6,000,000 shares — an estimated $50.7M sold.

BSN Capital Partners first reported a position in TEVA in Q4 2022 and held it in 1 quarter. The position peaked at $50.7M in Q4 2022. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

  • BSN Capital Partners reported no remaining Teva Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • BSN Capital Partners sold 6,000,000 Teva Pharmaceuticals shares in Q1 2023, an estimated $50.7M.
  • BSN Capital Partners first reported a position in Teva Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • BSN Capital Partners's Teva Pharmaceuticals position peaked at $50.7M in Q4 2022.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2023.

Based on BSN Capital Partners's 13F filing for Q1 2023, filed 20 Apr 2023.